05.11.2015 • News

Eli Lilly Expands R&D at Indianapolis

US drugmaker Eli Lilly plans to expand its research and development headquarters in Indianapolis, Indiana, to the tune of $70 million, adding floor space and a new disciplinary laboratory that will facilitate collaboration across multiple research functions.

The company said it expects to complete the expansion program by 2017. The new investment will further widen its footprint at its home base, where it spent $400 million two years ago to expand its insulin manufacturing capacity.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read